EVENT DOSSIER
Vijay Pande left a16z in June 2026, where he managed a fund worth nearly $4 billion, and co-founded the new company VZVC with Zack Werner. This organization makes only a few concentrated investments each year, has no partners, and operates using AI. Pande was previously known for developing the Folding@home project into a supercomputer for disease research. Later, under the influence of Marc Andreessen and Ben Horowitz, he took over the healthcare sector at a16z. In an interview with TechCrunch before Disrupt 2026, he shared his perspective on the biological field’s transition from “scientific discovery” to engineering, stating that AI is reducing the cost of clinical trials through synthetic data, although the success rate remains only 20%.
Vijay Pande 于去年 6 月离开管理近 40 亿美元基金的 a16z，与 Zack Werner 共同创立新公司 VZVC，该机构仅每年进行少数集中性投资，不设合伙人并依赖 AI 运营。Pande 此前因将 Folding@home 项目发展为疾病研究超级计算机而知名，后在 Marc Andreessen 和 Ben Horowitz 推动下接手 a16z 生物医疗板块。他在 Disrupt 2026 活动前接受 TechCrunch 采访，阐述了从“科学发现”向可工程化转变的生物领域观点，指出 AI 正通过合成数据降低临床试验成本，尽管成功率仍仅为 20%。